1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow ARPI: Enzalutamide: new trials by email Literature Review of ARPI: Enzalutamide trials Research Report on ARPI: Enzalutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC AAA617, ARPI: Abiraterone, ARPI: Enzalutamide - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 7 | 2025-09-11 | 2026-10-21 |
United States (1)